Microfluidics Market by Product (Chip, Sensor, Valve, Pump, Needle), Material (Silicon, Polymer), Application (Diagnostics (Clinical, PoC), Research (Proteomic, Genomics, Cell), Therapeutics (Drug Delivery, Wearables)), End User- Global Forecast to 2029
The Microfluidics market is projected to reach USD 32.67 Billion by 2029 from USD 22.43 in 2024, growing at a CAGR of 7.8% during the forecast period. The market for microfluidics is expanding due to a number of important factors. The growing requirement for point-of-care diagnostics is one of an important factor. The necessity for fast and accurate diagnosis has risen due to the increase in chronic diseases like cancer and diabetes, which is propelling the application of microfluidics in healthcare. Furthermore, the use of microfluidic devices is increasing due to innovations in drug delivery , organ-on-a-chip technology, and personalized medicine. Additionally, the market is driven by the rise in proteomics and genomics associated research.
“Polymers to account for largest market share in 2023.”
The market for microfluidics is propelled by polymers because of their their low costs, ease of production and adaptability. Microfluidic device manufacturing often requires polymers such as polydimethylsiloxane (PDMS), polymethyl methacrylate (PMMA), and cyclic olefin copolymer (COC). These polymers are helpful in the fabrication of microfluidic channels and structures. Moreover, as compared to conventional materials like silicon or glass, polymers are easier to mold and also, enables cheaper manufacturing costs. The biocompatible property of polymers makes them useful for a variety of medical applications, including medication delivery, lab-on-a-chip, and diagnostics. Due to such advantages, polymers accounts for the largest share in the microfluidics market.
“Hospital and Diagnostic Centers to register highest growth rate in the market during the forecast period.”
Various significant factors are propelling the growth of hospitals and diagnostic centers in the microfluidics industry. One important factor is the rising requirement for point-of-care diagnostics, as they provides quick, on-site testing that improves patient outcomes. Microfluidics play a major role in this positive outcome as it offers faster and precise result . Moreover, the requirement for efficacious diagnostics in clinical settings has risen due to the increase in infectious diseases like COVID-19. These equipment decreases cost, expedites testing methods, and improve precision and accuracy of diagnosis.
'Asia Pacific to register highest growth rate in the market during the forecast period.'
The highest CAGR was registered by the APAC region throughout the forecast period from 2024-2029. Asia Pacific comprise India, China, Japan, Australia, South Korea and RoAPAC. The demand for innovative technologies is increasing, especially in China, India, and Japan. Microfluidic devices for diagnostic and therapeutic applications are used due to the rise in prevalence of chronic and infectious diseases and the increase in focus on early diagnosis and preventative healthcare. The region's rising pharmaceutical and lifesciences industries are also undertaking research and development initiatives, which increases the requirement for microfluidics in personalized medicine and drug discovery.
A breakdown of the primary participants referred to for this report is provided below:
Research Coverage
The report comprise segmentation that covers end users, products, applications, and geographic regions. It also covers the key drivers, restraints, opportunities, and challenges impacting the growth trajectory of the microfluidics market. The research offers stakeholders an in-depth analysis of market potential and challenges, with a focus on major players and competitive landscapes. Moreover, micromarkets are analysed as per their overall impact to the global microfluidics sector, growth patterns, and potential. The analysis forecasts rise in market segment revenues, focusing on five key regions.
Key Benefits of Buying the Report:
The purpose of this research is to assist both new and existing players in the microfluidics market to assess the sustainability of their investments by providing detailed and knowledgeable information. It offers a dataset to assist in making key decisions. This report's potential to facilitate thorough risk evaluation and provide direction for investment decisions is one of its major benefit. Market segmentation according to end-users and geographical areas is provided in the study, that provides precise analysis and insights. It also provide significant trends, obstacles, opportunities, and drivers, giving stakeholders the information they require to make strategic decisions that help in their long-term growth.
The report provides the insights on the following pointers:
Analysis of the key drivers, restraints, opportunities, and challenges affecting the microfluidics market growth: Innovative technology and increase in prevalence of chronic diseases ; increased cost of devices and stringent regulations ; increase in number of diagnostic centers.
Product Development/Innovation: Overview of technologies, research & development ventures and launch of innovative product & service for the microfluidics industry.
Market Development: Details associated with profitable markets: this research studies the microfluidics business in various geographical regions.
Market Diversification: In-depth understanding of innovative products, unexamined regions, recent developments, and expenditures in the microfluidics market.
Competitive Assessment: Detailed analysis of market share, services and products offered and key strategies adopted by prominent players such as Danaher Corporation (US), Illumina Inc. (US), biomerieux (France), Thermo Fisher Scientific Inc. (US) and Abbott laboratories (US).
“Polymers to account for largest market share in 2023.”
The market for microfluidics is propelled by polymers because of their their low costs, ease of production and adaptability. Microfluidic device manufacturing often requires polymers such as polydimethylsiloxane (PDMS), polymethyl methacrylate (PMMA), and cyclic olefin copolymer (COC). These polymers are helpful in the fabrication of microfluidic channels and structures. Moreover, as compared to conventional materials like silicon or glass, polymers are easier to mold and also, enables cheaper manufacturing costs. The biocompatible property of polymers makes them useful for a variety of medical applications, including medication delivery, lab-on-a-chip, and diagnostics. Due to such advantages, polymers accounts for the largest share in the microfluidics market.
“Hospital and Diagnostic Centers to register highest growth rate in the market during the forecast period.”
Various significant factors are propelling the growth of hospitals and diagnostic centers in the microfluidics industry. One important factor is the rising requirement for point-of-care diagnostics, as they provides quick, on-site testing that improves patient outcomes. Microfluidics play a major role in this positive outcome as it offers faster and precise result . Moreover, the requirement for efficacious diagnostics in clinical settings has risen due to the increase in infectious diseases like COVID-19. These equipment decreases cost, expedites testing methods, and improve precision and accuracy of diagnosis.
'Asia Pacific to register highest growth rate in the market during the forecast period.'
The highest CAGR was registered by the APAC region throughout the forecast period from 2024-2029. Asia Pacific comprise India, China, Japan, Australia, South Korea and RoAPAC. The demand for innovative technologies is increasing, especially in China, India, and Japan. Microfluidic devices for diagnostic and therapeutic applications are used due to the rise in prevalence of chronic and infectious diseases and the increase in focus on early diagnosis and preventative healthcare. The region's rising pharmaceutical and lifesciences industries are also undertaking research and development initiatives, which increases the requirement for microfluidics in personalized medicine and drug discovery.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1–30%, Tier 2–42%, and Tier 3– 28%
- By Designation: C-level-- 14%, Director-level–10%, and Others–76%
- By Region: North America–40%, Europe-30%, Asia Pacific–22%, Rest of the World -8%.
Research Coverage
The report comprise segmentation that covers end users, products, applications, and geographic regions. It also covers the key drivers, restraints, opportunities, and challenges impacting the growth trajectory of the microfluidics market. The research offers stakeholders an in-depth analysis of market potential and challenges, with a focus on major players and competitive landscapes. Moreover, micromarkets are analysed as per their overall impact to the global microfluidics sector, growth patterns, and potential. The analysis forecasts rise in market segment revenues, focusing on five key regions.
Key Benefits of Buying the Report:
The purpose of this research is to assist both new and existing players in the microfluidics market to assess the sustainability of their investments by providing detailed and knowledgeable information. It offers a dataset to assist in making key decisions. This report's potential to facilitate thorough risk evaluation and provide direction for investment decisions is one of its major benefit. Market segmentation according to end-users and geographical areas is provided in the study, that provides precise analysis and insights. It also provide significant trends, obstacles, opportunities, and drivers, giving stakeholders the information they require to make strategic decisions that help in their long-term growth.
The report provides the insights on the following pointers:
Analysis of the key drivers, restraints, opportunities, and challenges affecting the microfluidics market growth: Innovative technology and increase in prevalence of chronic diseases ; increased cost of devices and stringent regulations ; increase in number of diagnostic centers.
Product Development/Innovation: Overview of technologies, research & development ventures and launch of innovative product & service for the microfluidics industry.
Market Development: Details associated with profitable markets: this research studies the microfluidics business in various geographical regions.
Market Diversification: In-depth understanding of innovative products, unexamined regions, recent developments, and expenditures in the microfluidics market.
Competitive Assessment: Detailed analysis of market share, services and products offered and key strategies adopted by prominent players such as Danaher Corporation (US), Illumina Inc. (US), biomerieux (France), Thermo Fisher Scientific Inc. (US) and Abbott laboratories (US).
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 MARKET STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH DESIGN
2.2.1 SECONDARY RESEARCH
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY RESEARCH
2.2.2.1 Key industry insights
2.3 MARKET SIZE ESTIMATION METHODOLOGY
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
2.3.1.2 Approach 2: Customer-based market estimation
2.3.1.3 Approach 3: Top-down approach
2.3.1.4 Approach 4: Primary interviews
2.3.1.5 Growth forecast
2.3.1.6 CAGR projection
2.3.2 TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 MARKET SHARE ASSESSMENT
2.6 RESEARCH ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.8 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 MICROFLUIDICS MARKET OVERVIEW
4.2 ASIA PACIFIC: MICROFLUIDICS MARKET, BY END USER AND COUNTRY (2023)
4.3 MICROFLUIDICS MARKET, BY REGION
4.4 GEOGRAPHIC SNAPSHOT OF MICROFLUIDICS MARKET
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing requirement for point-of-care testing
5.2.1.2 Rising technological advancements
5.2.1.3 Increasing focus on data precision and accuracy
5.2.1.4 Economic benefits associated with microfluidics
5.2.1.5 Portability with microfluidic chip miniaturization
5.2.1.6 Rising demand for effective sample analysis
5.2.2 RESTRAINTS
5.2.2.1 Stringent regulatory approval process
5.2.2.2 Integration of microfluidics into current workflow
5.2.3 OPPORTUNITIES
5.2.3.1 Emergence of 3D cell culture systems
5.2.3.2 Growth potential of emerging economies
5.2.3.3 Use of microfluidics in life sciences & pharmaceutical industries
5.2.4 CHALLENGES
5.2.4.1 Low adoption of microfluidic devices among end users
5.3 INDUSTRY TRENDS
5.3.1 E-HEALTH DIAGNOSTICS
5.3.2 INTEGRATION OF MICROFLUIDICS WITH 3D PRINTING
5.3.3 R&D INVESTMENTS FOR PRODUCT DEVELOPMENT
5.4 PORTER’S FIVE FORCES ANALYSIS
5.4.1 THREAT OF NEW ENTRANTS
5.4.2 THREAT OF SUBSTITUTES
5.4.3 BARGAINING POWER OF SUPPLIERS
5.4.4 BARGAINING POWER OF BUYERS
5.4.5 INTENSITY OF COMPETITIVE RIVALRY
5.5 KEY STAKEHOLDERS & BUYING CRITERIA
5.5.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.5.2 BUYING CRITERIA
5.6 REGULATORY LANDSCAPE
5.6.1 NORTH AMERICA
5.6.1.1 US
5.6.1.2 Canada
5.6.2 EUROPE
5.6.3 ASIA PACIFIC
5.6.3.1 Japan
5.6.3.2 China
5.6.3.3 India
5.6.4 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS
5.7 REIMBURSEMENT SCENARIO
5.8 ECOSYSTEM ANALYSIS
5.9 VALUE CHAIN ANALYSIS
5.9.1 RESEARCH & DEVELOPMENT
5.9.2 RAW MATERIAL PROCUREMENT & MANUFACTURING
5.9.3 MARKETING & SALES, DISTRIBUTION, AND POST-SALES SERVICES
5.10 SUPPLY CHAIN ANALYSIS
5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.12 IMPACT OF GEN AI ON MICROFLUIDICS MARKET
5.13 PATENT ANALYSIS
5.13.1 PATENT PUBLICATION TRENDS FOR MICROFLUIDICS
5.13.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
5.14 TRADE ANALYSIS
5.14.1 IMPORT DATA
5.14.2 EXPORT DATA
5.15 TECHNOLOGY ANALYSIS
5.15.1 KEY TECHNOLOGIES
5.15.1.1 Biosensor elements
5.15.1.2 Materials science
5.15.1.3 Microfabrication
5.15.1.4 Direct-writing
5.15.2 COMPLEMENTARY TECHNOLOGIES
5.15.2.1 MEMS
5.15.2.1.1 Green microfluidics
5.15.2.1.2 Microsensors/transducers
5.15.3 ADJACENT TECHNOLOGIES
5.15.3.1 3D inkjet printing
5.15.3.2 Lab-on-fiber
5.16 KEY CONFERENCES & EVENTS
5.17 PRICING ANALYSIS
5.17.1 AVERAGE SELLING PRICE TREND, BY REGION
5.17.2 AVERAGE SELLING PRICE TREND OF TOP 3 APPLICATIONS, BY KEY PLAYER
5.18 UNMET NEEDS/END-USER EXPECTATIONS IN MICROFLUIDICS MARKET
5.19 CASE STUDY ANALYSIS
5.19.1 CASE STUDY 1: MULTIPLEX MICROFLUIDIC CIRCUIT FOR BLOOD
VESSEL-ON-A-CHIP PERFUSION USING FLOWEZ
5.19.2 CASE STUDY 2: MICROFLUIDIC SYSTEM FOR ROBOTIC HAND PLAYING NINTENDO
5.19.3 CASE STUDY 3: 3D-PRINTED MICROFLUIDIC DEVICES USING POLYJET TECHNOLOGY
5.20 INVESTMENT & FUNDING SCENARIO
6 MICROFLUIDICS MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 MICROFLUIDICS-BASED DEVICES
6.2.1 HIGH UPTAKE OF POC TESTING AND ORGAN-ON-A-CHIP SYSTEMS
TO PROPEL MARKET
6.3 MICROFLUIDIC COMPONENTS
6.3.1 MICROFLUIDIC COMPONENTS, BY TYPE
6.3.1.1 Microfluidic chips
6.3.1.1.1 Chips to account for largest share of components market
6.3.1.2 Flow & pressure sensors
6.3.1.2.1 Utilization in lab diagnostics & research applications to drive market
6.3.1.3 Flow & pressure controllers
6.3.1.3.1 Cost-effectiveness and durability to boost demand
6.3.1.4 Microfluidic valves
6.3.1.4.1 Technological advancements to support market growth
6.3.1.5 Micropumps
6.3.1.5.1 Wide usage in drug delivery and glucose injections to fuel uptake
6.3.1.6 Microneedles
6.3.1.6.1 Miniscule size and painless patch application procedure to boost demand
6.3.1.7 Other microfluidic components
6.3.2 MICROFLUIDIC COMPONENTS, BY MATERIAL
6.3.2.1 Silicon
6.3.2.1.1 High precision and durability to boost demand
6.3.2.2 Polymers
6.3.2.2.1 Polymethyl Methacrylate (PMMA)
6.3.2.2.1.1 Durable alternative to glass to fuel uptake
6.3.2.2.2 Polydimethylsiloxane (PDMS)
6.3.2.2.2.1 Limited compatibility with specific solvents and acids to limit market adoption
6.3.2.2.3 Cyclic Olefin Copolymers
6.3.2.2.3.1 Low water absorption and enhanced electrical insulation properties to boost demand
6.3.2.2.4 Other polymers
6.3.2.3 Glass
6.3.2.3.1 High cost and brittleness to restrain market
7 MICROFLUIDICS MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 IVD
7.2.1 CLINICAL DIAGNOSTICS
7.2.1.1 Growing focus on early disease detection to drive market
7.2.2 POINT-OF-CARE TESTING (POCT)
7.2.2.1 High uptake of lab-on-a-chip technologies to fuel uptake
7.2.3 VETERINARY DIAGNOSTICS
7.2.3.1 Detection of toxins in food through LOC systems to support market growth
7.3 PHARMACEUTICAL & LIFE SCIENCE RESEARCH
7.3.1 LAB ANALYTICS
7.3.1.1 Proteomic analysis
7.3.1.1.1 Utilization of lab-on-a-chip devices for therapeutic development to drive market
7.3.1.2 Genomic analysis
7.3.1.2.1 Growing focus on NGS and digital PCR to boost demand
7.3.1.3 Cell-based assays
7.3.1.3.1 Drug-screening for cross-reaction & toxicity testing to support market growth
7.3.1.4 Capillary electrophoresis
7.3.1.4.1 Growing applications for environmental monitoring and clinical diagnostics to fuel uptake
7.3.2 MICRODISPENSING
7.3.2.1 Suitability for low-viscosity applications to support market growth
7.3.3 MICROREACTORS
7.3.3.1 High uptake by leading companies for process optimization to fuel market
7.4 THERAPEUTICS
7.4.1 DRUG DELIVERY
7.4.1.1 Utilization of microneedles for painless and precise delivery to drive market
7.4.2 WEARABLE DEVICES
7.4.2.1 Integration of microfluidics-based wearable devices to support market growth
8 MICROFLUIDICS MARKET, BY END USER
8.1 INTRODUCTION
8.2 HOSPITALS AND DIAGNOSTIC CENTERS
8.2.1 AVAILABILITY OF TECHNOLOGICALLY ADVANCED EQUIPMENT AND FOCUS ON EARLY DISEASE DIAGNOSIS TO BOOST DEMAND
8.3 ACADEMIC & RESEARCH INSTITUTES
8.3.1 INVESTMENTS IN BIOMEDICAL & LIFE SCIENCE RESEARCH TO SUPPORT MARKET GROWTH
8.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
8.4.1 GROWING FOCUS ON BIOMARKER & DRUG DISCOVERY TO PROPEL MARKET
9 MICROFLUIDICS MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
9.2.2 US
9.2.2.1 High healthcare expenditure and wide adoption of technologically advanced products to drive market
9.2.3 CANADA
9.2.3.1 Government funds and focus on research to support market growth
9.3 EUROPE
9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
9.3.2 GERMANY
9.3.2.1 Growing focus on proteomics & genomics research to drive market
9.3.3 FRANCE
9.3.3.1 Favorable government support for R&D to drive market
9.3.4 UK
9.3.4.1 Rising cases of chronic diseases and increasing demand for POC testing to boost demand
9.3.5 ITALY
9.3.5.1 Innovative development of microfluidic chips to boost demand
9.3.6 SPAIN
9.3.6.1 Growth in pharmaceutical industry to fuel uptake
9.3.7 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
9.4.2 CHINA
9.4.2.1 Growing focus on nanotechnology to drive market
9.4.3 JAPAN
9.4.3.1 High investments in academic research activities to propel market
9.4.4 INDIA
9.4.4.1 Increasing prevalence of CVD and diabetes to support market growth
9.4.5 AUSTRALIA
9.4.5.1 Rising incidence of infectious diseases to fuel uptake
9.4.6 SOUTH KOREA
9.4.6.1 Increasing R&D expenditure to drive growth
9.4.7 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
9.5.2 BRAZIL
9.5.2.1 Increasing development of disease diagnostics kits to fuel uptake
9.5.3 MEXICO
9.5.3.1 Rising prevalence of chronic diseases to boost demand for POC testing
9.5.4 REST OF LATIN AMERICA
9.6 MIDDLE EAST & AFRICA
9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
9.6.2 GCC COUNTRIES
9.6.2.1 Adoption of advanced microfluidic devices to support market growth
9.6.3 REST OF MIDDLE EAST & AFRICA
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 KEY PLAYER STRATEGY/RIGHT TO WIN
10.3 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN MICROFLUIDICS MARKET
10.4 REVENUE ANALYSIS
10.5 MARKET SHARE ANALYSIS BY KEY PLAYERS,2023
10.6 RANKING OF KEY MARKET PLAYERS
10.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
10.7.1 STARS
10.7.2 EMERGING LEADERS
10.7.3 PERVASIVE PLAYERS
10.7.4 PARTICIPANTS
10.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
10.7.5.1 Company footprint
10.7.5.2 Product footprint
10.7.5.3 Application footprint
10.7.5.4 End-user footprint
10.7.5.5 Region footprint
10.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
10.8.1 PROGRESSIVE COMPANIES
10.8.2 RESPONSIVE COMPANIES
10.8.3 DYNAMIC COMPANIES
10.8.4 STARTING BLOCKS
10.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
10.8.5.1 Detailed list of key startup/SME players
10.8.5.2 Competitive benchmarking of key emerging players/startups
10.9 COMPANY VALUATION & FINANCIAL METRICS
10.9.1 FINANCIAL METRICS
10.9.2 COMPANY VALUATION
10.10 BRAND/PRODUCT COMPARATIVE ANALYSIS
10.11 COMPETITIVE SCENARIO
10.11.1 PRODUCT LAUNCHES & APPROVALS
10.11.2 DEALS
10.11.3 EXPANSIONS
10.11.4 OTHER DEVELOPMENTS
11 COMPANY PROFILES
11.1 KEY PLAYERS
11.1.1 DANAHER CORPORATION
11.1.1.1 Business overview
11.1.1.2 Products offered
11.1.1.3 Recent developments
11.1.1.3.1 Deals
11.1.1.3.2 Expansions
11.1.1.4 MnM view
11.1.1.4.1 Key strengths
11.1.1.4.2 Strategic choices
11.1.1.4.3 Weaknesses & competitive threats
11.1.2 ILLUMINA, INC.
11.1.2.1 Business overview
11.1.2.2 Products offered
11.1.2.3 Recent developments
11.1.2.3.1 Product launches & approvals
11.1.2.3.2 Deals
11.1.2.4 MnM view
11.1.2.4.1 Key strengths
11.1.2.4.2 Strategic choices
11.1.2.4.3 Weaknesses & competitive threats
11.1.3 BIOMЙRIEUX
11.1.3.1 Business overview
11.1.3.2 Products offered
11.1.3.3 Recent developments
11.1.3.3.1 Product launches & approvals
11.1.3.4 MnM view
11.1.3.4.1 Key strengths
11.1.3.4.2 Strategic choices
11.1.3.4.3 Weaknesses & competitive threats
11.1.4 THERMO FISHER SCIENTIFIC INC.
11.1.4.1 Business overview
11.1.4.2 Products offered
11.1.4.3 Recent developments
11.1.4.3.1 Product launches & approvals
11.1.4.3.2 Deals
11.1.4.3.3 Expansions
11.1.4.4 MnM view
11.1.4.4.1 Key strengths
11.1.4.4.2 Strategic choices
11.1.4.4.3 Weaknesses & competitive threats
11.1.5 ABBOTT LABORATORIES
11.1.5.1 Business overview
11.1.5.2 Products offered
11.1.5.3 MnM view
11.1.5.3.1 Key strengths
11.1.5.3.2 Strategic choices
11.1.5.3.3 Weaknesses & competitive threats
11.1.6 PARKER HANNIFIN CORP
11.1.6.1 Business overview
11.1.6.2 Products offered
11.1.7 SMC CORPORATION
11.1.7.1 Business overview
11.1.7.2 Products offered
11.1.7.3 Recent developments
11.1.7.3.1 Product launches
11.1.8 IDEX CORPORATION
11.1.8.1 Business overview
11.1.8.2 Products offered
11.1.8.3 Recent developments
11.1.8.3.1 Deals
11.1.9 FORTIVE
11.1.9.1 Business overview
11.1.9.2 Products offered
11.1.10 PERKINELMER INC.
11.1.10.1 Business overview
11.1.10.2 Products offered
11.1.10.3 Recent developments
11.1.10.3.1 Product launches
11.1.10.3.2 Deals
11.1.11 AGILENT TECHNOLOGIES, INC.
11.1.11.1 Business overview
11.1.11.2 Products offered
11.1.11.3 Recent developments
11.1.11.3.1 Product launches
11.1.11.3.2 Deals
11.1.11.3.3 Expansions
11.1.12 BIO-RAD LABORATORIES, INC.
11.1.12.1 Business overview
11.1.12.2 Products offered
11.1.12.3 Recent developments
11.1.12.3.1 Product launches
11.1.12.3.2 Deals
11.1.13 BECTON, DICKINSON AND COMPANY
11.1.13.1 Business overview
11.1.13.2 Products offered
11.1.13.3 Recent developments
11.1.13.3.1 Product launches & approvals
11.1.13.3.2 Deals
11.1.13.3.3 Expansions
11.1.14 F. HOFFMANN-LA ROCHE LTD.
11.1.14.1 Business overview
11.1.14.2 Products offered
11.1.14.3 Recent developments
11.1.14.3.1 Product launches & approvals
11.1.14.3.2 Deals
11.1.15 STANDARD BIOTOOLS
11.1.15.1 Business overview
11.1.15.2 Products offered
11.1.15.3 Recent developments
11.1.15.3.1 Product launches & approvals
11.1.15.3.2 Deals
11.1.16 QUIDELORTHO CORPORATION
11.1.16.1 Business overview
11.1.16.2 Products offered
11.1.16.3 Recent developments
11.1.16.3.1 Product approvals
11.1.16.3.2 Deals
11.1.16.3.3 Expansions
11.1.17 HOLOGIC, INC.
11.1.17.1 Business overview
11.1.17.2 Products offered
11.1.17.3 Recent developments
11.1.17.3.1 Product approvals
11.1.17.3.2 Deals
11.1.18 AIGNEP S.P.A.
11.1.18.1 Business overview
11.1.18.2 Products offered
11.1.18.3 Recent developments
11.1.18.3.1 Deals
11.1.19 DOLOMITE MICROFLUIDICS
11.1.19.1 Business overview
11.1.19.2 Products offered
11.1.19.3 Recent developments
11.1.19.3.1 Product launches & approvals
11.1.19.3.2 Deals
11.1.19.3.3 Other developments
11.1.20 ELVEFLOW
11.1.20.1 Business overview
11.1.20.2 Products offered
11.2 OTHER PLAYERS
11.2.1 NANOSTRING TECHNOLOGIES
11.2.2 NORTIS INC.
11.2.3 INNOVATIVE BIOCHIPS, LLC
11.2.4 FLUIDIC ANALYTICS
11.2.5 UFLUIDIX
11.2.6 HORIBA
11.2.7 MICRONIT B.V.
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 MARKET STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH DESIGN
2.2.1 SECONDARY RESEARCH
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY RESEARCH
2.2.2.1 Key industry insights
2.3 MARKET SIZE ESTIMATION METHODOLOGY
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
2.3.1.2 Approach 2: Customer-based market estimation
2.3.1.3 Approach 3: Top-down approach
2.3.1.4 Approach 4: Primary interviews
2.3.1.5 Growth forecast
2.3.1.6 CAGR projection
2.3.2 TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 MARKET SHARE ASSESSMENT
2.6 RESEARCH ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.8 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 MICROFLUIDICS MARKET OVERVIEW
4.2 ASIA PACIFIC: MICROFLUIDICS MARKET, BY END USER AND COUNTRY (2023)
4.3 MICROFLUIDICS MARKET, BY REGION
4.4 GEOGRAPHIC SNAPSHOT OF MICROFLUIDICS MARKET
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing requirement for point-of-care testing
5.2.1.2 Rising technological advancements
5.2.1.3 Increasing focus on data precision and accuracy
5.2.1.4 Economic benefits associated with microfluidics
5.2.1.5 Portability with microfluidic chip miniaturization
5.2.1.6 Rising demand for effective sample analysis
5.2.2 RESTRAINTS
5.2.2.1 Stringent regulatory approval process
5.2.2.2 Integration of microfluidics into current workflow
5.2.3 OPPORTUNITIES
5.2.3.1 Emergence of 3D cell culture systems
5.2.3.2 Growth potential of emerging economies
5.2.3.3 Use of microfluidics in life sciences & pharmaceutical industries
5.2.4 CHALLENGES
5.2.4.1 Low adoption of microfluidic devices among end users
5.3 INDUSTRY TRENDS
5.3.1 E-HEALTH DIAGNOSTICS
5.3.2 INTEGRATION OF MICROFLUIDICS WITH 3D PRINTING
5.3.3 R&D INVESTMENTS FOR PRODUCT DEVELOPMENT
5.4 PORTER’S FIVE FORCES ANALYSIS
5.4.1 THREAT OF NEW ENTRANTS
5.4.2 THREAT OF SUBSTITUTES
5.4.3 BARGAINING POWER OF SUPPLIERS
5.4.4 BARGAINING POWER OF BUYERS
5.4.5 INTENSITY OF COMPETITIVE RIVALRY
5.5 KEY STAKEHOLDERS & BUYING CRITERIA
5.5.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.5.2 BUYING CRITERIA
5.6 REGULATORY LANDSCAPE
5.6.1 NORTH AMERICA
5.6.1.1 US
5.6.1.2 Canada
5.6.2 EUROPE
5.6.3 ASIA PACIFIC
5.6.3.1 Japan
5.6.3.2 China
5.6.3.3 India
5.6.4 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS
5.7 REIMBURSEMENT SCENARIO
5.8 ECOSYSTEM ANALYSIS
5.9 VALUE CHAIN ANALYSIS
5.9.1 RESEARCH & DEVELOPMENT
5.9.2 RAW MATERIAL PROCUREMENT & MANUFACTURING
5.9.3 MARKETING & SALES, DISTRIBUTION, AND POST-SALES SERVICES
5.10 SUPPLY CHAIN ANALYSIS
5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.12 IMPACT OF GEN AI ON MICROFLUIDICS MARKET
5.13 PATENT ANALYSIS
5.13.1 PATENT PUBLICATION TRENDS FOR MICROFLUIDICS
5.13.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
5.14 TRADE ANALYSIS
5.14.1 IMPORT DATA
5.14.2 EXPORT DATA
5.15 TECHNOLOGY ANALYSIS
5.15.1 KEY TECHNOLOGIES
5.15.1.1 Biosensor elements
5.15.1.2 Materials science
5.15.1.3 Microfabrication
5.15.1.4 Direct-writing
5.15.2 COMPLEMENTARY TECHNOLOGIES
5.15.2.1 MEMS
5.15.2.1.1 Green microfluidics
5.15.2.1.2 Microsensors/transducers
5.15.3 ADJACENT TECHNOLOGIES
5.15.3.1 3D inkjet printing
5.15.3.2 Lab-on-fiber
5.16 KEY CONFERENCES & EVENTS
5.17 PRICING ANALYSIS
5.17.1 AVERAGE SELLING PRICE TREND, BY REGION
5.17.2 AVERAGE SELLING PRICE TREND OF TOP 3 APPLICATIONS, BY KEY PLAYER
5.18 UNMET NEEDS/END-USER EXPECTATIONS IN MICROFLUIDICS MARKET
5.19 CASE STUDY ANALYSIS
5.19.1 CASE STUDY 1: MULTIPLEX MICROFLUIDIC CIRCUIT FOR BLOOD
VESSEL-ON-A-CHIP PERFUSION USING FLOWEZ
5.19.2 CASE STUDY 2: MICROFLUIDIC SYSTEM FOR ROBOTIC HAND PLAYING NINTENDO
5.19.3 CASE STUDY 3: 3D-PRINTED MICROFLUIDIC DEVICES USING POLYJET TECHNOLOGY
5.20 INVESTMENT & FUNDING SCENARIO
6 MICROFLUIDICS MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 MICROFLUIDICS-BASED DEVICES
6.2.1 HIGH UPTAKE OF POC TESTING AND ORGAN-ON-A-CHIP SYSTEMS
TO PROPEL MARKET
6.3 MICROFLUIDIC COMPONENTS
6.3.1 MICROFLUIDIC COMPONENTS, BY TYPE
6.3.1.1 Microfluidic chips
6.3.1.1.1 Chips to account for largest share of components market
6.3.1.2 Flow & pressure sensors
6.3.1.2.1 Utilization in lab diagnostics & research applications to drive market
6.3.1.3 Flow & pressure controllers
6.3.1.3.1 Cost-effectiveness and durability to boost demand
6.3.1.4 Microfluidic valves
6.3.1.4.1 Technological advancements to support market growth
6.3.1.5 Micropumps
6.3.1.5.1 Wide usage in drug delivery and glucose injections to fuel uptake
6.3.1.6 Microneedles
6.3.1.6.1 Miniscule size and painless patch application procedure to boost demand
6.3.1.7 Other microfluidic components
6.3.2 MICROFLUIDIC COMPONENTS, BY MATERIAL
6.3.2.1 Silicon
6.3.2.1.1 High precision and durability to boost demand
6.3.2.2 Polymers
6.3.2.2.1 Polymethyl Methacrylate (PMMA)
6.3.2.2.1.1 Durable alternative to glass to fuel uptake
6.3.2.2.2 Polydimethylsiloxane (PDMS)
6.3.2.2.2.1 Limited compatibility with specific solvents and acids to limit market adoption
6.3.2.2.3 Cyclic Olefin Copolymers
6.3.2.2.3.1 Low water absorption and enhanced electrical insulation properties to boost demand
6.3.2.2.4 Other polymers
6.3.2.3 Glass
6.3.2.3.1 High cost and brittleness to restrain market
7 MICROFLUIDICS MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 IVD
7.2.1 CLINICAL DIAGNOSTICS
7.2.1.1 Growing focus on early disease detection to drive market
7.2.2 POINT-OF-CARE TESTING (POCT)
7.2.2.1 High uptake of lab-on-a-chip technologies to fuel uptake
7.2.3 VETERINARY DIAGNOSTICS
7.2.3.1 Detection of toxins in food through LOC systems to support market growth
7.3 PHARMACEUTICAL & LIFE SCIENCE RESEARCH
7.3.1 LAB ANALYTICS
7.3.1.1 Proteomic analysis
7.3.1.1.1 Utilization of lab-on-a-chip devices for therapeutic development to drive market
7.3.1.2 Genomic analysis
7.3.1.2.1 Growing focus on NGS and digital PCR to boost demand
7.3.1.3 Cell-based assays
7.3.1.3.1 Drug-screening for cross-reaction & toxicity testing to support market growth
7.3.1.4 Capillary electrophoresis
7.3.1.4.1 Growing applications for environmental monitoring and clinical diagnostics to fuel uptake
7.3.2 MICRODISPENSING
7.3.2.1 Suitability for low-viscosity applications to support market growth
7.3.3 MICROREACTORS
7.3.3.1 High uptake by leading companies for process optimization to fuel market
7.4 THERAPEUTICS
7.4.1 DRUG DELIVERY
7.4.1.1 Utilization of microneedles for painless and precise delivery to drive market
7.4.2 WEARABLE DEVICES
7.4.2.1 Integration of microfluidics-based wearable devices to support market growth
8 MICROFLUIDICS MARKET, BY END USER
8.1 INTRODUCTION
8.2 HOSPITALS AND DIAGNOSTIC CENTERS
8.2.1 AVAILABILITY OF TECHNOLOGICALLY ADVANCED EQUIPMENT AND FOCUS ON EARLY DISEASE DIAGNOSIS TO BOOST DEMAND
8.3 ACADEMIC & RESEARCH INSTITUTES
8.3.1 INVESTMENTS IN BIOMEDICAL & LIFE SCIENCE RESEARCH TO SUPPORT MARKET GROWTH
8.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
8.4.1 GROWING FOCUS ON BIOMARKER & DRUG DISCOVERY TO PROPEL MARKET
9 MICROFLUIDICS MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
9.2.2 US
9.2.2.1 High healthcare expenditure and wide adoption of technologically advanced products to drive market
9.2.3 CANADA
9.2.3.1 Government funds and focus on research to support market growth
9.3 EUROPE
9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
9.3.2 GERMANY
9.3.2.1 Growing focus on proteomics & genomics research to drive market
9.3.3 FRANCE
9.3.3.1 Favorable government support for R&D to drive market
9.3.4 UK
9.3.4.1 Rising cases of chronic diseases and increasing demand for POC testing to boost demand
9.3.5 ITALY
9.3.5.1 Innovative development of microfluidic chips to boost demand
9.3.6 SPAIN
9.3.6.1 Growth in pharmaceutical industry to fuel uptake
9.3.7 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
9.4.2 CHINA
9.4.2.1 Growing focus on nanotechnology to drive market
9.4.3 JAPAN
9.4.3.1 High investments in academic research activities to propel market
9.4.4 INDIA
9.4.4.1 Increasing prevalence of CVD and diabetes to support market growth
9.4.5 AUSTRALIA
9.4.5.1 Rising incidence of infectious diseases to fuel uptake
9.4.6 SOUTH KOREA
9.4.6.1 Increasing R&D expenditure to drive growth
9.4.7 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
9.5.2 BRAZIL
9.5.2.1 Increasing development of disease diagnostics kits to fuel uptake
9.5.3 MEXICO
9.5.3.1 Rising prevalence of chronic diseases to boost demand for POC testing
9.5.4 REST OF LATIN AMERICA
9.6 MIDDLE EAST & AFRICA
9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
9.6.2 GCC COUNTRIES
9.6.2.1 Adoption of advanced microfluidic devices to support market growth
9.6.3 REST OF MIDDLE EAST & AFRICA
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 KEY PLAYER STRATEGY/RIGHT TO WIN
10.3 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN MICROFLUIDICS MARKET
10.4 REVENUE ANALYSIS
10.5 MARKET SHARE ANALYSIS BY KEY PLAYERS,2023
10.6 RANKING OF KEY MARKET PLAYERS
10.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
10.7.1 STARS
10.7.2 EMERGING LEADERS
10.7.3 PERVASIVE PLAYERS
10.7.4 PARTICIPANTS
10.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
10.7.5.1 Company footprint
10.7.5.2 Product footprint
10.7.5.3 Application footprint
10.7.5.4 End-user footprint
10.7.5.5 Region footprint
10.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
10.8.1 PROGRESSIVE COMPANIES
10.8.2 RESPONSIVE COMPANIES
10.8.3 DYNAMIC COMPANIES
10.8.4 STARTING BLOCKS
10.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
10.8.5.1 Detailed list of key startup/SME players
10.8.5.2 Competitive benchmarking of key emerging players/startups
10.9 COMPANY VALUATION & FINANCIAL METRICS
10.9.1 FINANCIAL METRICS
10.9.2 COMPANY VALUATION
10.10 BRAND/PRODUCT COMPARATIVE ANALYSIS
10.11 COMPETITIVE SCENARIO
10.11.1 PRODUCT LAUNCHES & APPROVALS
10.11.2 DEALS
10.11.3 EXPANSIONS
10.11.4 OTHER DEVELOPMENTS
11 COMPANY PROFILES
11.1 KEY PLAYERS
11.1.1 DANAHER CORPORATION
11.1.1.1 Business overview
11.1.1.2 Products offered
11.1.1.3 Recent developments
11.1.1.3.1 Deals
11.1.1.3.2 Expansions
11.1.1.4 MnM view
11.1.1.4.1 Key strengths
11.1.1.4.2 Strategic choices
11.1.1.4.3 Weaknesses & competitive threats
11.1.2 ILLUMINA, INC.
11.1.2.1 Business overview
11.1.2.2 Products offered
11.1.2.3 Recent developments
11.1.2.3.1 Product launches & approvals
11.1.2.3.2 Deals
11.1.2.4 MnM view
11.1.2.4.1 Key strengths
11.1.2.4.2 Strategic choices
11.1.2.4.3 Weaknesses & competitive threats
11.1.3 BIOMЙRIEUX
11.1.3.1 Business overview
11.1.3.2 Products offered
11.1.3.3 Recent developments
11.1.3.3.1 Product launches & approvals
11.1.3.4 MnM view
11.1.3.4.1 Key strengths
11.1.3.4.2 Strategic choices
11.1.3.4.3 Weaknesses & competitive threats
11.1.4 THERMO FISHER SCIENTIFIC INC.
11.1.4.1 Business overview
11.1.4.2 Products offered
11.1.4.3 Recent developments
11.1.4.3.1 Product launches & approvals
11.1.4.3.2 Deals
11.1.4.3.3 Expansions
11.1.4.4 MnM view
11.1.4.4.1 Key strengths
11.1.4.4.2 Strategic choices
11.1.4.4.3 Weaknesses & competitive threats
11.1.5 ABBOTT LABORATORIES
11.1.5.1 Business overview
11.1.5.2 Products offered
11.1.5.3 MnM view
11.1.5.3.1 Key strengths
11.1.5.3.2 Strategic choices
11.1.5.3.3 Weaknesses & competitive threats
11.1.6 PARKER HANNIFIN CORP
11.1.6.1 Business overview
11.1.6.2 Products offered
11.1.7 SMC CORPORATION
11.1.7.1 Business overview
11.1.7.2 Products offered
11.1.7.3 Recent developments
11.1.7.3.1 Product launches
11.1.8 IDEX CORPORATION
11.1.8.1 Business overview
11.1.8.2 Products offered
11.1.8.3 Recent developments
11.1.8.3.1 Deals
11.1.9 FORTIVE
11.1.9.1 Business overview
11.1.9.2 Products offered
11.1.10 PERKINELMER INC.
11.1.10.1 Business overview
11.1.10.2 Products offered
11.1.10.3 Recent developments
11.1.10.3.1 Product launches
11.1.10.3.2 Deals
11.1.11 AGILENT TECHNOLOGIES, INC.
11.1.11.1 Business overview
11.1.11.2 Products offered
11.1.11.3 Recent developments
11.1.11.3.1 Product launches
11.1.11.3.2 Deals
11.1.11.3.3 Expansions
11.1.12 BIO-RAD LABORATORIES, INC.
11.1.12.1 Business overview
11.1.12.2 Products offered
11.1.12.3 Recent developments
11.1.12.3.1 Product launches
11.1.12.3.2 Deals
11.1.13 BECTON, DICKINSON AND COMPANY
11.1.13.1 Business overview
11.1.13.2 Products offered
11.1.13.3 Recent developments
11.1.13.3.1 Product launches & approvals
11.1.13.3.2 Deals
11.1.13.3.3 Expansions
11.1.14 F. HOFFMANN-LA ROCHE LTD.
11.1.14.1 Business overview
11.1.14.2 Products offered
11.1.14.3 Recent developments
11.1.14.3.1 Product launches & approvals
11.1.14.3.2 Deals
11.1.15 STANDARD BIOTOOLS
11.1.15.1 Business overview
11.1.15.2 Products offered
11.1.15.3 Recent developments
11.1.15.3.1 Product launches & approvals
11.1.15.3.2 Deals
11.1.16 QUIDELORTHO CORPORATION
11.1.16.1 Business overview
11.1.16.2 Products offered
11.1.16.3 Recent developments
11.1.16.3.1 Product approvals
11.1.16.3.2 Deals
11.1.16.3.3 Expansions
11.1.17 HOLOGIC, INC.
11.1.17.1 Business overview
11.1.17.2 Products offered
11.1.17.3 Recent developments
11.1.17.3.1 Product approvals
11.1.17.3.2 Deals
11.1.18 AIGNEP S.P.A.
11.1.18.1 Business overview
11.1.18.2 Products offered
11.1.18.3 Recent developments
11.1.18.3.1 Deals
11.1.19 DOLOMITE MICROFLUIDICS
11.1.19.1 Business overview
11.1.19.2 Products offered
11.1.19.3 Recent developments
11.1.19.3.1 Product launches & approvals
11.1.19.3.2 Deals
11.1.19.3.3 Other developments
11.1.20 ELVEFLOW
11.1.20.1 Business overview
11.1.20.2 Products offered
11.2 OTHER PLAYERS
11.2.1 NANOSTRING TECHNOLOGIES
11.2.2 NORTIS INC.
11.2.3 INNOVATIVE BIOCHIPS, LLC
11.2.4 FLUIDIC ANALYTICS
11.2.5 UFLUIDIX
11.2.6 HORIBA
11.2.7 MICRONIT B.V.
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
